Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185208 · ClinicalTrials.gov registry record · Phase 4
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
A Phase 4 study of Mild Cognitive Impairment, sponsored by Ariel Gildengers, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT03185208 is a Phase 4 study of Mild Cognitive Impairment that has completed, run by Ariel Gildengers, MD. The registered enrollment target is 83 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03185208, a Phase 4 study of Mild Cognitive Impairment, has completed, sponsored by Ariel Gildengers, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Lithium Carbonate
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185208
The ClinicalTrials.gov registry entry for NCT03185208 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (93% lower). The listed sponsor is Ariel Gildengers, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03185208 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03185208 about?
NCT03185208 is a clinical study titled "Lithium As a Treatment to Prevent Impairment of Cognition in Elders". Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more rese...
What is the current status of trial NCT03185208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2018-02-02. Estimated completion is 2024-08-06.
What conditions does trial NCT03185208 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
What interventions are being tested in trial NCT03185208?
The interventions under investigation include: Placebo oral capsule (DRUG), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT03185208?
This trial is sponsored by Ariel Gildengers, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03185208 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Water-based Activity to Enhance Recall in Veterans
ACTIVE NOT RECRUITING · Phase 4
-
Combination Treatment Study for Memory Impairment and Depression
COMPLETED · Phase 4
-
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
COMPLETED · Phase 4
-
Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia
COMPLETED · Phase 4
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.